Quarterly and annual results disclosed under 8-K Item 2.02.
Roblox Corp reported its first quarter ended March 31, 2024 results: revenue $801.3 million, net income $271.9 million.
“and supplemental materials on the Roblox investor relations website at ir.roblox.com. First Quarter 2024 Financial, Operational, and Liquidity Highlights • Revenue was $801.3 million, up 22% year-over-year. • Bookings 1 were $923.8 million, up 19% year-over-year. • Net loss attributable to common stockholders was $270.6 million, while consolidated net loss”
ANAVEX LIFE SCIENCES CORP. reported financial results for its fiscal quarter ended March 31, 2024.
“On May 9, 2024, Anavex Life Sciences Corp. (the “ Company ”) issued a press release reporting financial results for its fiscal quarter ended March 31, 2024”
HOULIHAN LOKEY, INC. reported fourth quarter ended March 31, 2024 results: revenue $520 million, net income $81 million, EPS $1.18 per diluted share.
“Year 2024 Revenues of $1.91 billion – – Fiscal Year 2024 Diluted EPS of $4.11 – – Adjusted Fiscal Year 2024 Diluted EPS of $4.49 – – Fourth Quarter Fiscal 2024 Revenues of $520 million – – Fourth Quarter Fiscal 2024 Diluted EPS of $1.18 – – Adjusted Fourth Quarter Fiscal 2024 Diluted EPS of $1.27 – – Announces an Increase in the Quarterly Dividend to $0.57 per”
HOULIHAN LOKEY, INC. reported fiscal year ended March 31, 2024 results: revenue $1.91 billion, net income $280 million, EPS $4.11 per diluted share.
“by a specific reference in such filing. --- EX-99.1 (EX-99.1) --- Houlihan Lokey Reports Fiscal Year and Fourth Quarter 2024 Financial Results – Fiscal Year 2024 Revenues of $1.91 billion – – Fiscal Year 2024 Diluted EPS of $4.11 – – Adjusted Fiscal Year 2024 Diluted EPS of $4.49 – – Fourth Quarter Fiscal 2024 Revenues of $520 million – – Fourth Quarter Fiscal”
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. updated its end of 2024 guidance (raised).
“Initiated activities to reduce annualized run-rate operating expenses and the Company expects to achieve above the high end of our previously provided range of non-GAAP reduction of $50 million to $75 million by the end of 2024 compared to our prior guidance of 5% operating expense growth.”
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. reported first quarter ended March 31, 2024 results: net income Net loss for the first quarter of 2024 was $78.2 million, compared to a net loss of $88.0 million for the first quarter, EPS Net loss per share for the first quarter of 2024 was $0.29, compared to net loss per share of $0.36 for the first quarte.
“Revenue of $38.8 million compared with $38.9 million in the prior-year period.”
Sotherly Hotels Inc. reported the quarter ended March 31, 2024 results: revenue $46,548, net income Net loss attributable to common stockholders $ (659 ), EPS Net loss per common share - diluted $ (0.03 ).
“ended March 31, 2024. The Company’s results include the following*: Three Months Ended March 31, 2024 March 31, 2023 ($ in thousands except per share data) Total revenue $ 46,548 $ 43,491 Net loss attributable to common stockholders (659 ) (582 ) EBITDA 10,785 9,948 Hotel EBITDA 12,360 12,079 FFO attributable to common stockholders and unitholders 3,961”
bluebird bio, Inc. reported the three months ended March 31, 2024 results: revenue $18.6 million.
“– 15 patient starts to date in 2024 (11 ZYNTEGLO, 3 SKYSONA, 1 LYFGENIA); 85 to 105 patient starts anticipated across the portfolio in 2024 – – First quarter 2024 net revenue of $18.6 million – – Management to host conference call today, May 9, 2024 at 8:00 am ET – SOMERVILLE, Mass. – May 9, 2024 – bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “Company”)”
TechTarget Holdings Inc. reported three (3) months ended March 31, 2024 results: revenue approximately $51.6 million, net income approximately $10.1 million.
“For Q1 2024: • GAAP revenue was approximately $51.6 million, a decrease of 10%. Net loss was approximately $10.1 million, a decrease of 713%”
MEDICAL PROPERTIES TRUST INC reported first quarter ended March 31, 2024 results: net income ($736 million) (($1.23) per share), EPS ($1.23) per share.
“Net loss for the first quarter ended March 31, 2024 was ($736 million) (($1.23) per share) compared to net income of $33 million ($0.05 per share) in the year earlier period.”
COLLEGIUM PHARMACEUTICAL, INC reported the quarter ended March 31, 2024 results: revenue $144.9 million, net income $27.7 million, EPS $0.86 GAAP earnings per share (basic) and $0.71 GAAP earnings per share (diluted). Guidance reaffirmed.
“under Item 2.02 of this Current Report on Form 8-K. --- EX-99.1 (EX-99.1) --- Collegium Reports First Quarter 2024 Financial Results – Generated Q1’24 Net Revenue of $144.9 Million – – Delivered Q1’24 Record Belbuca ® Revenue of $50.7 Million; Total Prescriptions Up 4.2% Year-over-Year – – Achieved Q1’24 GAAP Net Income of $27.7 Million vs. Q1’23 GAAP”
H&R BLOCK INC reported fiscal 2024 third quarter ended March 31, 2024 results: revenue $2.2 billion. Guidance raised.
“and double-digit EPS growth that allows for continued, significant returns of capital to our shareholders through dividends and share repurchases." • Total revenue of $2.2 billion increased by $91.2 million, or 4%, to the prior year. The increase was primarily due to a higher net average charge and higher company-owned volumes in the Assisted category”
Lite Strategy, Inc. reported three and nine months ended March 31, 2024 results: net income As of March 31, 2024, MEI had $56.6 million in cash, cash equivalents, and short-term investments with no outstanding de.
“As of March 31, 2024, MEI had $56.6 million in cash, cash equivalents, and short-term investments with no outstanding debt.”
Lite Strategy, Inc. reported financial results for third quarter ended March 31, 2024.
“On May 9, 2024, MEI Pharma, Inc. (the “Company”) issued a press release announcing its financial results for its third quarter ended March 31, 2024.”
Oncternal Therapeutics, Inc. reported for the quarter ended March 31, 2024 results: revenue $0.6 million, net income Net loss for the first quarter was $8.4 million, or a net loss of $2.83 per share, EPS $2.83 per share, basic and diluted.
“T cell therapy ‒ Clinical data update in mid-2024 ‒ Additional clinical data readouts in the fourth quarter of 2024 First Quarter 2024 Financial Results Our grant revenue was $0.6 million for the first quarter ended March 31, 2024. Our total operating expenses for the first quarter ended March 31, 2024 were $9.3 million, including $1.4 million in non-cash”
NELNET INC reported the first quarter of 2024 results: net income $73.2 million, EPS $1.97 per share.
“Nelnet (NYSE: NNI) today reported GAAP net income of $73.2 million, or $1.97 per share, for the first quarter of 2024”
VAPOTHERM INC reported first quarter ended March 31, 2024 results: revenue $19.1 million, net income $14.8 million net loss, EPS $2.31 per share.
“first quarter 2024 financial results and related highlights. First Quarter 2024 Financial Results and Related Highlights • Net revenue for the first quarter of 2024 was $19.1 million, an increase of 7.9% as compared to the first quarter of 2023 o Disposables revenue increased by 13.5% as compared to the first quarter of 2023 • Gross margin in the first”
LIQUIDITY SERVICES INC reported quarter ended March 31, 2024 results: revenue $91.5 million, net income $5.7 million, EPS $0.18 per share.
“results for the quarter ended March 31, 2024, as compared to the corresponding prior year quarter: • Gross Merchandise Volume (GMV) of $319.4 million, up 13%, and Revenue of $91.5 million, up 12% • GAAP Net Income of $5.7 million, up 35%, and GAAP Diluted Earnings Per Share (EPS) of $0.18, up 38% • Non-GAAP Adjusted EBITDA of $12.1 million, up $2.2 million, and”
FIRST ADVANTAGE CORP reported Quarter ended March 31, 2024 results: revenue 169.4, net income -2.9, EPS -0.02.
“for the first quarter ended March 31, 2024. Key Financials (Amounts in millions, except per share data and percentages) Three Months Ended March 31, 2024 2023 Change Revenues $ 169.4 $ 175.5 (3.5 )% (Loss) income from operations $ (0.7 ) $ 11.3 NM Net (loss) income $ (2.9 ) $ 1.9 NM Net (loss) income margin (1.7 )% 1.1 % NA Diluted net (loss) income per share”
CareDx, Inc. reported the first quarter ended March 31, 2024 results: revenue $72.0 million, net income net loss was $16.7 million, EPS $0.32. Guidance raised.
“CareDx, Inc. (Nasdaq: CDNA) — today reported financial results for the first quarter ended March 31, 2024. First Quarter 2024 Highlights • Reported first quarter revenue of $72.0 million. • Revenue for Testing Services of $53.8 million, an increase of 15% as compared to the fourth quarter 2023. • Grew testing services patients results for the third consecutive”
NEPHROS INC reported first quarter ended March 31, 2024 results: revenue $3.5 million, net income Net loss of $0.2 million.
“Nephros Announces Financial Results for Quarter Ended March 31, 2024 First-Quarter Net Revenue of $3.5 Million”
Cytosorbents Corp reported the quarter ended March 31, 2024 results: revenue $9.8 million.
“$7.9 million in Q1 2023, an increase of 14%, and up 22% sequentially from $7.3 million in Q4 2023 · Total revenue, including product sales and grant income, for Q1 2024 was $9.8 million, an increase of 4% compared to $9.4 million in Q1 2023 · Q1 2024 product gross margins increased to approximately 76%, (excluding the impact of a one-time,”
AMICUS THERAPEUTICS, INC. updated its the first quarter ended March 31, 2024 guidance (raised).
“On May 9, 2024, Amicus Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended March 31, 2024.”
CEVA INC reported the quarter ended March 31, 2024 results: revenue $22.1 million, net income $5.4 million, EPS $0.23.
“with Arm through Arm Total Design to accelerate development of end-to-end 5G SoCs for Infrastructure and NTN Satellites Total revenue for the first quarter of 2024 was $22.1 million, compared to $26.3 million reported for the first quarter of 2023. Licensing and related revenue for the first quarter of 2024 was $11.4 million, compared to $18.2 million”
RADIANT LOGISTICS, INC reported three and nine months ended March 31, 2024 results: revenue $184.6 million, net income net loss attributable to Radiant Logistics, Inc. of $0.7 million, EPS $0.02 loss per basic and fully diluted share.
“services company, today reported financial results for the three and nine months ended March 31, 2024. Financial Highlights – Three Months Ended March 31, 2024 • Revenues of $184.6 million for the third fiscal quarter ended March 31, 2024, down $59.6 million or 24.4%, compared to revenues of $244.2 million for the comparable prior year period. • Gross profit of”
CONSTELLATION ENERGY GENERATION LLC reported full-year 2024 results: EPS $7.23 - $8.03 per share. Guidance reaffirmed.
“Affirming full-year 2024 Adjusted (non-GAAP) Operating Earnings guidance range of $7.23 - $8.03 per share”
CONSTELLATION ENERGY GENERATION LLC reported the first quarter of 2024 results: EPS GAAP Net Income of $2.78 per share.
“GAAP Net Income of $2.78 per share and Adjusted (non-GAAP) Operating Earnings of $1.82 per share for the first quarter of 2024”
CUTERA INC reported the first quarter ended March 31, 2024 results: revenue $38.8 million. Guidance reaffirmed.
“Cutera, Inc. (Nasdaq: CUTR) (“Cutera” or the “Company”), a leading provider of aesthetic and dermatology solutions, today reported financial results for the first quarter ended March 31, 2024. • Consolidated revenue for the first quarter of 2024 of $38.8 million.”
COGENT COMMUNICATIONS HOLDINGS, INC. reported first quarter of 2024 results: revenue $266.2 million.
“Cogent Communications Holdings, Inc. (NASDAQ: CCOI) (“Cogent”) today announced service revenue of $266.2 million for the three months ended March 31, 2024, a decrease of 2.2% from the three months ended December 31, 2023 and an increase of 73.3% from the three months ended March 31, 2023.”
INSULET CORP updated its Full Year 2024 guidance (raised).
“Insulet Reports First Quarter 2024 Revenue Increase of 23% Year-Over-Year Raising Full Year Revenue and Operating Margin Guidance”
INSULET CORP reported first quarter ended March 31, 2024 results: revenue 441.7 million, net income 51.5 million, EPS 0.73. Guidance raised.
“First quarter 2024 revenue of $441.7 million, up 23.3%, or 22.8% in constant currency 1 , compared to $358.1 million in the prior year, exceeds the guidance range of 17% to 20% in constant currency due to revenue outperformance for all product lines”
APPLIED OPTOELECTRONICS, INC. reported first quarter ended March 31, 2024 results: revenue $40.7 million, net income $23.2 million, EPS $0.60 per basic share.
“drivers remain strong across our end markets and we believe we are well positioned to capitalize on these opportunities.” First Quarter 2024 Financial Summary · GAAP revenue was $40.7 million, compared with $53.0 million in the first quarter of 2023 and $60.5 million in the fourth quarter of 2023. · GAAP gross margin was 18.7%, compared with 17.4% in the first quarter”
AMN HEALTHCARE SERVICES INC reported financial results for the fiscal quarter ended March 31, 2024.
“On May 9, 2024, AMN Healthcare Services, Inc. reported its results for the fiscal quarter ended March 31, 2024.”
NEXSTAR MEDIA GROUP, INC. reported the quarter ended March 31, 2024 results: revenue $1.28 billion, net income $167 million.
“an ATSC 3.0, or NextGen TV, signal from a Nexstar owned or operated station following the Chicago and San Diego market launches. Net Revenue. Record first quarter net revenue of $1.28 billion, increased by $27 million, or 2.1%, reflecting growth in distribution revenue, partially offset by a slight decline in advertising and other revenue. Approximately 59% of”
HireQuest, Inc. reported the first quarter ended March 31, 2024 results: revenue $8.4 million, net income $1.7 million, EPS $0.12 per diluted share.
“First Quarter 2024 Summary ● Franchise royalties decreased 16.0% to $7.8 million compared to $9.3 million in the prior year period. ● Total revenue decreased 14.6% to $8.4 million compared to $9.9 million in the prior year period. ● Selling, general and administrative (“SG&A”) expenses were $5.6 million, a decrease of 3.9% compared to $5.8 million in the prior year period. Excluding net workers’ compensation expense of $572,000 and MRI ad fund expense of $101,000, SG&A for the quarter would have decreased 12.6%. ● Income from operations decreased 36.6% to $2.1 million compared to $3.3 million in the prior year period. ● Net income from continuing operations was $1.7 million, or $0.12 per diluted share, a decrease of 27.0% compared to net income from continuing operations of $2.3 million, or $0.17 per diluted share in the prior year period.”
MACROGENICS INC reported financial results for quarter ended March 31, 2024.
“On May 9, 2024, MacroGenics, Inc. (the "Company") announced financial and operating results as of and for the quarter ended March 31, 2024.”
GYRE THERAPEUTICS, INC. reported the three months ended March 31, 2024 results: revenue $27.2 million.
“of the condensed consolidated financial statements. Financial Results for the Quarter Ended March 31, 2024 • Revenues: For the three months ended March 31, 2024, revenues were $27.2 million as a result of Gyre’s indirect controlling interest in Gyre Pharmaceuticals. For the three months ended March 31, 2023, revenues were $24.9 million. The increase was driven by a”
PDF SOLUTIONS INC reported first quarter ended March 31, 2024 results: revenue $41.3 million, net income $0.4 million, EPS ($0.01) per diluted share. Guidance reaffirmed.
“31, 2024. Financial Highlights of First Quarter 2024 and Other Updates ● Analytics revenues of $38.5 million, up 6% over last year’s comparable quarter ● Quarterly revenues of $41.3 million, up 1% over last year’s comparable quarter ● GAAP gross margin of 67% and Non-GAAP gross margin of 72% ● GAAP diluted loss per share of $0.01 and non-GAAP diluted earnings per”
TAPESTRY, INC. reported fiscal third quarter ended March 30, 2024 results: revenue $1.48 billion, net income $139 million, EPS $0.60.
“levels 12% below the prior year, reflecting the Company’s focus on disciplined inventory management. Overview of Fiscal 2024 Third Quarter Financial Results • Net sales totaled $1.48 billion compared to $1.51 billion in the prior year period, representing a decline of 2% on a reported basis. Excluding a currency headwind of approximately 160 basis points, sales”
INSMED Inc updated its the first quarter ended March 31, 2024 guidance (reaffirmed).
“On May 9, 2024, Insmed Incorporated (the “Company”) issued a press release regarding its financial results for the three months ended March 31, 2024.”
AMERICAN REALTY INVESTORS INC reported three months ended March 31, 2024 results: revenue $11.3 million, net income $1.8 million, EPS $0.11 per diluted share.
“Farms to February 28, 2026 at an interest rate of 7.50%. Financial Results Rental revenues increased $0.3 million from $11.0 million for the three months ended March 31, 2023 to $11.3 million for the three months ended March 31, 2024 . The increase in rental revenue is primarily due to $0.7 million increase at our multifamily properties offset in part by a decrease of”
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. reported financial results for the first quarter ended March 30, 2024.
“On May 9, 2024, Charles River Laboratories International, Inc. issued a press release providing financial results for the first quarter ended March 30, 2024.”
PLUG POWER INC reported the first quarter ended March 31, 2024 results: revenue $120.3 million, EPS $0.46 loss per share.
“The Company reported revenue of $120.3 million and EPS loss of $0.46 for the quarter ended March 31, 2024.”
Spectrum Brands Holdings, Inc. updated its fiscal second quarter ended March 31, 2024 guidance (raised).
“On May 9, 2024, the Company issued a press release (the "Earnings Press Release") discussing, among other things, its financial results for its fiscal second quarter ended March 31, 2024.”
AKAMAI TECHNOLOGIES INC reported first quarter ended March 31, 2024 results: revenue $987 million, net income GAAP net income per diluted share of $1.11, EPS GAAP net income per diluted share was $1.11.
“AKAMAI REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS First quarter revenue of $987 million”
ZIFF DAVIS, INC. reported the first quarter ended March 31, 2024 results: revenue $314.5 million, net income $10.6 million, EPS $0.23. Guidance reaffirmed.
“growth in our subscription and licensing revenues, as we continue to pursue a balanced business model." FIRST QUARTER 2024 RESULTS • Q1 2024 quarterly revenues increased 2.4% to $314.5 million compared to $307.1 million for Q1 2023. • Income from operations increased 36.3% to $35.9 million compared to $26.3 million for Q1 2023. • Net income (loss) (1) increased to”
LIGHTBRIDGE Corp reported the first quarter ended March 31, 2024 results: net income Net loss was $2.8 million for the first quarter ended March 31, 2024.
“Net loss was $2.8 million for the first quarter ended March 31, 2024, compared to $2.0 million for the first quarter ended March 31, 2023.”
Flux Power Holdings, Inc. reported fiscal third quarter ended March 31, 2024 results: revenue $14.5 million.
“30, 2023 $ 28,544,000 $ 8,102,000 $ 14,797,000 $ 21,849,000 December 31, 2023 $ 21,849,000 $ 26,552,000 $ 18,344,000 $ 30,057,000 March 31, 2024 $ 30,057,000 $ 4,030,000 $ 14,457,000 $ 19,630,000 CEO Commentary Continued “Looking ahead, we are highly focused on expanding sales and marketing initiatives to secure new customer relationships and support”
NETSCOUT SYSTEMS INC reported financial results for the fourth fiscal quarter and the fiscal year 2024 each ended March 31, 2024.
“On May 9, 2024, NetScout Systems, Inc. (the “Company”) issued a press release regarding its financial results for the fourth fiscal quarter and the fiscal year 2024 each ended March 31, 2024”
EGAIN Corp reported fiscal 2024 third quarter ended March 31, 2024 results: revenue Total revenue was $22.4 million, net income GAAP net income was $1.5 million, EPS $0.05 per share on a basic and diluted basis.
“Total revenue was $22.4 million, down 3% year over year.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.